Valuation: PROT DIAG

Market Cap 216M 22.61M 19.65M 18.29M 16.79M 31.71M 2.16B 32.2M 84.62M 1.07B 84.9M 83.03M 3.6B P/E 2024
-2.94x
P/E 2025 -4.28x
Enterprise Value 175M 18.35M 15.95M 14.85M 13.63M 25.74M 1.75B 26.14M 68.68M 872M 68.91M 67.39M 2.92B EV / Sales 2024
2.16x
EV / Sales 2025 4.15x
Free-Float
12.26%
Yield 2024 *
-
Yield 2025 -
1 day+2.29%
1 week-4.18%
1 month+39.84%
6 months-6.18%
1 week 17.34
Extreme 17.34
17.9
1 month 12.5
Extreme 12.5
18.68
Current year 12.46
Extreme 12.46
21
1 year 12.46
Extreme 12.46
25.4
3 years 11.7
Extreme 11.7
138
5 years 11.7
Extreme 11.7
183.4
10 years 11.7
Extreme 11.7
806
Manager TitleAgeSince
Chief Executive Officer 62 30/06/2020
Director of Finance/CFO 68 -
Chief Tech/Sci/R&D Officer 57 -
Director TitleAgeSince
Director/Board Member 70 31/12/2019
Director/Board Member 62 -
Director/Board Member 52 30/09/2023
Change 5-day change 1-year change 3-year change Capi.($)
+2.29%-4.18%-30.08%-87.26% 22.61M
-1.89%-1.36%+19.78%-40.36% 15.7B
+4.47%+7.46%+3.82%+107.97% 1.77B
+1.21%+4.49%-26.48%-80.29% 1.14B
-1.73%+2.33%-33.93%+16.19% 980M
+1.29%+7.31%-44.39%-52.50% 655M
+0.93%+7.41%-45.64%-53.16% 543M
+1.08%+2.47%+55.85%-51.37% 472M
-0.81%+1.33%-52.64%-61.03% 374M
-0.81%+5.14%-13.72%-32.63% 368M
Average +0.60%+2.57%-16.74%-33.44% 2.2B
Weighted average by Cap. -0.94%-0.19%+9.12%-29.16%

Financials

2024 2025
Net sales 36.33M 3.81M 3.31M 3.08M 2.83M 5.34M 364M 5.43M 14.26M 181M 14.3M 13.99M 607M 42.2M 4.42M 3.85M 3.58M 3.29M 6.21M 422M 6.3M 16.56M 210M 16.62M 16.25M 705M
Net income -26.94M -2.82M -2.46M -2.29M -2.1M -3.96M -270M -4.02M -10.57M -134M -10.61M -10.37M -450M -49.71M -5.21M -4.53M -4.22M -3.87M -7.31M -498M -7.42M -19.51M -248M -19.57M -19.14M -831M
Net Debt -15.73M -1.65M -1.43M -1.33M -1.23M -2.31M -157M -2.35M -6.18M -78.4M -6.2M -6.06M -263M -40.61M -4.26M -3.7M -3.44M -3.16M -5.97M -406M -6.07M -15.94M -202M -15.99M -15.64M -678M
Logo PROT DIAG
Prolight Diagnostics AB (publ) is a Sweden-based medical technology company. Together with Technology Partners, the Company develops patient-close test systems based on patented technology, for use in so-called Point of Care Testing (POCT). POCT tests are performed outside the traditional hospital laboratory, small mobile instruments enable testing near the patient and provide quick test answers. The Company focuses on the heart marker troponin.
Employees
22
Date Price Change Volume
31/07/26 SEK 17.90 +2.29% 13,029
30/07/26 SEK 17.50 +0.92% 3,963
29/07/26 SEK 17.34 -1.48% 5,062
28/07/26 SEK 17.60 +1.15% 4,435
27/07/26 SEK 17.40 -6.85% 16,863
  1. Stock Market
  2. Stocks
  3. PRLD Stock